Ioana Moldovan, MD
Rheumatology · San Bernardino, CANPI 1740201557
Payments from drug & device makers
Across 1,298 payments — averaging $98.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$93K
- AbbVie$17K
- UCB, Inc.$4K
- Johnson & Johnson$2K
- Novartis$2K
- Mallinckrodt Hospital Products Inc.$2K
- plus $9K from 31 others
What the payments were for
- Consulting fees$2,3072%
- Speaking & faculty fees$88,70669%
- Travel & lodging$9,3657%
- Food & beverage$27,41221%
- Education$5270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 383 | $92,751 |
| AbbVie | 216 | $16,944 |
| UCB, Inc. | 102 | $3,710 |
| Johnson & Johnson | 96 | $2,239 |
| Novartis | 96 | $1,716 |
| Mallinckrodt Hospital Products Inc. | 54 | $1,620 |
| GSK | 54 | $1,447 |
| Bristol Myers Squibb | 7 | $1,251 |
| AstraZeneca(2 entities) | 32 | $1,039 |
| Pfizer | 53 | $965 |
| Lilly USA, LLC | 70 | $964 |
| Aurinia Pharma U.S., Inc. | 15 | $655 |
| E.r. Squibb & Sons, L.L.C. | 34 | $634 |
| Genentech USA, Inc. | 8 | $381 |
| ANI Pharmaceuticals, Inc. | 11 | $242 |
| Janssen Scientific Affairs, LLC | 2 | $230 |
| Radius Health, Inc. | 7 | $179 |
| Sobi, Inc | 7 | $178 |
| Boehringer Ingelheim | 6 | $159 |
| Sanofi | 4 | $155 |
| Mallinckrodt Enterprises LLC | 9 | $125 |
| Corcept Therapeutics | 1 | $125 |
| Sanofi-aventis U.S. LLC | 4 | $91 |
| Shire North American Group Inc | 4 | $76 |
| Sandoz | 4 | $71 |
| Fresenius Kabi USA, LLC | 3 | $60 |
| Kyowa Kirin, Inc. | 2 | $45 |
| Octapharma USA, Inc. | 2 | $42 |
| Gilead | 2 | $38 |
| Scilex Pharmaceuticals Inc. | 2 | $33 |
| Celltrion USA Inc. | 1 | $30 |
| Medexus Pharma, Inc. | 2 | $29 |
| Tonix Medicines, Inc. | 1 | $25 |
| Bioventus LLC | 1 | $19 |
| Alvogen Inc | 1 | $18 |
| Bayer | 1 | $16 |
| Mylan Institutional Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$128,318 in reported general payments places this provider in the 85th percentile of 808 rheumatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 263 | $1,957,567 |
| Humira(Cf) PenAdalimumab | 213 | $1,542,346 |
| RinvoqUpadacitinib | 104 | $671,091 |
| Orencia ClickjectAbatacept | 68 | $419,889 |
| Skyrizi PenRisankizumab-Rzaa | 16 | $397,722 |
| BenlystaBelimumab | 44 | $204,523 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 77 | $184,634 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 16 | $119,563 |
| ForteoTeriparatide | 27 | $117,285 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 21 | $108,579 |
| Xeljanz XrTofacitinib Citrate | 17 | $96,572 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 13 | $95,502 |
| OtezlaApremilast | 19 | $91,760 |
| SimponiGolimumab | 11 | $79,468 |
| Humira(Cf)Adalimumab | 12 | $77,117 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira(Cf) | $16,944 | $748,208116 claims |
| AmgenEvenity (2 Syringes), Otezla, Prolia, Rayos | $92,751 | $372,742144 claims |
| GSKBenlysta | $1,447 | $204,52344 claims |
| Lilly USA, LLCForteo | $964 | $117,28527 claims |
| Johnson & JohnsonSimponi | $2,239 | $79,46811 claims |
| PfizerXeljanz, Premarin | $965 | $71,59123 claims |
| UCB, Inc.Cimzia (2 Pack) | $3,710 | $61,22811 claims |
| BayerKerendia | $16 | $11,59118 claims |
| Medexus Pharma, Inc.Rasuvo | $29 | $11,22720 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 808 rheumatology providers in California.
Other rheumatology in San Bernardino
- Samy MetyasCovina$12.9M
- Christine ThaiHuntington Beach$8.5M
- Tien-I SuWhittier$8.4M
- Eric LeeUpland$6.9M
- Orrin TroumSanta Monica$6.9M
- Shirley PangFullerton$5.7M
- William RobinsonStanford$5.1M
- Dan laTujunga$5.1M
- Christina Charles-SchoemanLos Angeles$4.8M
- Suneet GrewalWest Hollywood$3.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.